TABLE 2.
Impact of garenoxacin dosing interval on in vivo efficacy against S. pneumoniae 10813 and S. aureus 33591
| Dosing interval | ED25 (95% CI)a | ED50 (95% CI) | ED75 (95% CI) | Static dose (95% CI) | 1 log kill (95% CI) |
|---|---|---|---|---|---|
| S. pneumoniae | |||||
| q3h | 11.5 (8.2-14.8) | 23 (16.3-29.7) | 46.2 (32.8-59.6) | 18.2 (12.9-23.5) | 25.8 (18.3-33.3) |
| q6h | 8.3 (3.7-12.8) | 18.4 (8.2-28.6) | 41.1 (18.5-63.7) | 16 (7.2-24.8) | 25 (11.2-38.8) |
| q12h | 14.4 (0.6-28.2) | 31 (0.7-61.3) | 64 (3-125) | 31 (0.7-61.3) | 50.3 (23.3-78.3) |
| q24h | 12.9 (1.0-24.9) | 38.8 (1.2-76.4) | 115 (111-227) | 65.7 (1.7-130) | >128 |
| S. aureus | |||||
| q3h | 2.85 (2.6-3.1) | 3.40 (3.1-3.8) | 4.96 (4.5-5.5) | 4.33 (3.9-4.8) | 5.84 (5.3-6.4) |
| q6h | 1.05 (1.0-1.2) | 4.07 (2.9-5.2) | 15.9 (11.1-20.5) | 10.0 (7.0-13.0) | 30 (21.1-38.1) |
| q12h | 1.56 (1.4-1.8) | 3.44 (3.0-3.8) | 7.60 (6.7-8.5) | 5.95 (5.0-7.0) | 11.5 (10.1-12.9) |
| q24h | 2.9 (1.5-4.3) | 7.46 (3.8-11.1) | 19.1 (9.7-28.5) | 7.91 (4.0-11.8) | 26.6 (13.6-39.6) |
a
CI, confidence interval.